Lonza announced the release of a new technical note that provides toxicity, wound healing and cosmetic researchers with a faster method for constructing three-dimensional (3D) full-thickness skin models that closely resemble native skin.
Compared with its two-dimensional (2D) counterpart, 3D cell culture is increasingly being recognized as a more effective in vitro approach for studying epidermal cell biology as it more closely mimics the in vivo cellular environment. However, conventional 3D cell culture technology typically requires 28-30 days to develop full-thickness skin models, which can have an impact on experiment timelines.
Lonza’s new technical note demonstrates how the RAFT™ 3D Cell Culture System has been optimized to allow full-thickness skin models to be developed in approximately 22-24 days. Titled “Construction of a Full-Thickness Skin Model Using RAFT™ 3D Cell Culture System,” the technical note also highlights how the RAFT™ System provides a versatile 3D culture platform for the addition of other cell types, helping scientists to build more-complex skin models for advanced wound healing, toxicity and cosmetic research.
“To overcome the current time and optimization challenges with conventional 3D cell culture technology, we wanted to provide researchers with a simple-to-use cell culture system that would enable full-thickness skin models to be easily constructed and in a more timely fashion,” said Lubna Hussain, Senior Global Product Manager for Primary Cells at Lonza. “As highlighted in the technical note, by combining our high-quality dermal primary cells and media products with the RAFT™3D Cell Culture System, we can offer a more comprehensive solution for the development of physiologically relevant skin models. We have coupled these products with optimized protocols and customized scientific support to provide researchers an easier way to implement these challenging 3D models.”
The technical note is available on bioscience.lonza.com/raft-white-papers-and-protocols
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer’s healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com